Abstract
The medical management of thyroid-associated ophthalmopathy has been, and remains a clinical challenge. Several drugs have been used. Systemic steroids seem to be beneficial in patients with active disease. The evidence for the remaining drugs reported to be potentially useful, is unconvincing.
Get full access to this article
View all access options for this article.